Search the GHTC website

Global health R&D delivers for Texas

US government investment in global health R&D has delivered

$855.2 million
to Texas research institutions
13,400+ new jobs
for Texas
Texas's top USG-funded global health R&D institutions

Texas's top USG-funded global health R&D institutions

University of Texas Medical Branch at Galveston
$221 million
Texas Biomedical Research Institute (Texas Biomed, formally Southwest Foundation for Medical Research)
$115.5 million
University of Texas Southwestern Medical Center at Dallas
$87 million
Baylor College of Medicine
$76.4 million
Texas A&M University
$58 million
University of Texas Health Science Center at Houston
$35 million
Texas A&M Agrilife Research
$33.7 million
University of Texas at Austin
$29.1 million
University of Texas Health Science Center at San Antonio
$25.1 million
University of Texas at El Paso
$24.4 million
Luminex Corporation
$20.3 million
Methodist Hospital Research Institute
$16.8 million
Texas Tech University
$14.2 million
Rice University
$10.4 million
University of Texas at Tyler Health Science Center
$9.3 million
University of Texas at San Antonio
$8.7 million
University of Houston
$7 million
PharmaReview Corporation
$6.3 million
University of Texas MD Anderson Cancer Center
$5.6 million
$5.2 million
Southwest Research Institute
$4.8 million
Via Therapeutics
$4.4 million
KJ Biosciences LLC
$4 million
Yaso Therapeutics
$3.7 million
AI Biosciences
$3.5 million
Texas A&M Engineering Experiment Station
$3.5 million
Accel Diagnostics
$2.1 million
University of North Texas Health Science Center
$1.7 million
University of Texas at Arlington
$1.5 million
Baylor University
$1.3 million
Baylor Scott & White Research Institute
$1.2 million
Consultants in Disease and Injury Control (CDIC)*
$1.2 million
Operational Technologies Corporation
$1.2 million
8 Hills Pharma
$999 thousand
Fannin Partners
$978 thousand
Texas Children's Hospital Center for Vaccine Development
$963 thousand
Base Pair Biotechnologies Inc.
$866 thousand
Genomics USA Inc.
$811 thousand
Covalent Bioscience Inc.
$773 thousand
University of Texas at Dallas
$642 thousand
Pulmonescence Diagnostics
$582 thousand
Southern Methodist University
$548 thousand
Omm Scientific Inc.*
$540 thousand
University of the Incarnate Word
$501 thousand
Emergent Biotechnologies*
$385 thousand
Bio-Synthesis Inc.
$384 thousand
Texas Christian University
$330 thousand
Melax Technologies
$324 thousand
7 Hills Pharma
$322 thousand
$300 thousand
Entvantage Dx
$293 thousand
Synshark LLC
$257 thousand
Accacia International LLC*
$190 thousand
$183 thousand
Paratus Diagnostics LLC*
$176 thousand
Fabrico Technology, Inc.
$167 thousand
Nanohmics Inc.
$167 thousand
Bioo Scientific Corporation*
$127 thousand
$107 thousand
Heliowave Technologies LLC
$58 thousand
Resonant Sensors Inc.
$51 thousand

Texas's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Buruli ulcer
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Snakbite envenoming
Reproductive health
Salmonella infections
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Rheumatic fever
Global health R&D at work in Texas

Baylor College of Medicine and Texas Children’s Hospital have teamed up to advance vaccine research for a myriad of neglected and emerging health threats, including hookworm, schistosomiasis, Chagas disease, leishmaniasis, and severe acute respiratory syndrome (SARS). Most notably, the collaborators developed a COVID-19 vaccine that is approved and has been administered to more than 100 million people in India and Indonesia. The vaccine, which was developed using more traditional vaccine technology, is relatively cheap and easy to manufacture compared to mRNA shots. Its developers have also offered the intellectual property for the vaccine for free to all manufacturers, intending to make it a more affordable option for low-income countries to produce and distribute to their populations.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: US Department of State